Browsing Tag
Carole Ho
3 posts
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.
Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history
Big pharma has $1.3 trillion to deploy and $230 billion in revenue going off-patent by 2030. The 2026 deal map shows where the panic is real.
Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies
Eli Lilly agrees to acquire Centessa Pharmaceuticals for $6.3B, gaining orexin sleep drug cleminorexton. Read the full strategic analysis.